Mosanna Therapeutics is a clinical-stage biotech company pioneering a novel pharmaceutical approach to treating obstructive sleep apnea (OSA) with an easily administered nasal spray. Designed to help restore the body’s natural airway control during sleep, Mosanna’s lead therapy, MOS118, offers a drug-based alternative to traditional mechanical treatments and is currently being evaluated in a Phase 1 clinical trial. Founded in 2022, the company has raised more than $80 million from investors including Pivotal bioVenture Partners, EQT Life Sciences, Forbion, Norwest, Broadview Ventures, Forty51 Ventures, Supermoon Capital and High-Tech Gründerfonds (HTGF). Mosanna has offices in Redwood City, California and Basel, Switzerland. 

Biotechnology

Clinical Trials

Pharmaceutical

Therapeutics

Mosanna Therapeutics

David Weber

Grayson Judge

Matthew Naunheim

Mike Masterson

Ben MacHielse

Prof Marc Brown Cchem Frsc

Mosanna Therapeutics

Org chart

Teams

Offices